[opensourcepharma] OSP @ RHH 2015 will happen Sep 1-3

Tue Jun 9 15:27:39 UTC 2015

There is also an active repurposing program at UC-Davis
<http://ucdmc.ucdavis.edu/welcome/features/20090520_web_portal/index.html>.
The scientist behind the Johns Hopkins effort moved to Harvard, and I lost
track of him.

b

On Tue, Jun 9, 2015 at 11:17 AM, Jaykumar Menon, Prof. <
jaykumar.menon at mcgill.ca> wrote:

>  A tremendous paper Dimitrios, thanks for it.   And great  comments Mat
> and Bernard and Samir.
>
>
>
> To continue the thought experiment, I wonder if there is a gaping need for
> more effort on what is perhaps the lowest of the low hanging fruit:
>
> a)      Focused on approved drugs only
>
> b)      With no IP hurdle  (generic, or otherwise no hurdle)
>
> c)       Comprehensive or at least somewhat broad.
>
> (I see a few narrower efforts- Univ of British Columbia, and Chicago-based
> Cures within Reach).  The Johns Hopkins Clinical Compound Screening
> Initiative (JHCCSI) looks promising, though their web site seems defunct.
>
> d)      Open source and crowd powered
>
>
>
> j
>
>
>
> *From:* Dimitrios Tzalis [mailto:dtzalis at taros.de]
> *Sent:* Tuesday, June 09, 2015 5:50 AM
> *To:* Jaykumar Menon, Prof.
> *Cc:* opensourcepharma at lists.okfn.org; Peter Kolb
> *Subject:* Re: [opensourcepharma] OSP @ RHH 2015 will happen Sep 1-3
>
>
>
> Dear Jay,
>
>
>
> this indeed is a very interesting approach and has gotten quite some
> attention for quite some time for obvious reasons.  There are ongoing
> activites in this area in the US as well as in Europe. There are quite a
> few initiatives where ADMET data is being made available on potential drug
> candidates in an Open Source approach. There was last year good review in
> 2013 on this topic by Minna Allarakhia
>
>
>
>
> http://www.academia.edu/4964147/Open-source_approaches_for_the_repurposing_of_existing_or_failed_candidate_drugs
>
>
>
>
>
>
>
> *From:* SKB IGIB EMAIL [mailto:skb at igib.res.in]
> *Sent:* Tuesday, June 09, 2015 3:32 AM
> *To:* Bernard Munos; Jaykumar Menon, Prof.
>
> *Cc:* opensourcepharma at lists.okfn.org
> *Subject:* Re: [opensourcepharma] OSP @ RHH 2015 will happen Sep 1-3
>
>
>
> Dear Bernard, I completely agree with you. We have taken this up as a low
> hanging fruits. I am in Weizmann Institute attending an International
> Conference Deep Sequencing Meets Structural biolology. Ada Yonath. Gave
> some new idea on combination drugs to combat drug resistance. regards. Samir
>
>
>
> Sent from my BlackBerry 10 smartphone.
>
> *From: *Bernard Munos
>
> *Sent: *Tuesday, June 9, 2015 09:53
>
> *To: *Jaykumar Menon, Prof.
>
> *Cc: *opensourcepharma at lists.okfn.org
>
> *Subject: *Re: [opensourcepharma] OSP @ RHH 2015 will happen Sep 1-3
>
>
>
> Jay,
>
>
>
> Drug repurposing is a powerful innovation model that should definitely be
> part of our remit. It is championed by NIH because for many diseases --
> especially rare ones -- it is the most economical way to speed new
> therapies to market.
>
>
>
> For the record, folks who are steeped in this thing distinguish between
> drug repurposing (the use of an *approved* drug for an entirely new
> indication) from drug rescue (the resurrection of a drug candidate that was
> abandoned *before it was approved*, but has been subsequently found to
> have activity against an entirely different disease).
>
>
>
> The scientific rationale for drug repurposing is compelling. I keep a
> database of all the drugs approved that have been found to work on
> something else, and their number is in the hundreds. This is often the
> result of drugs modulating multiple targets that impact various diseases.
>
>
>
> IP is not an issue with drug repurposing (at least not in the US) because
> many molecules are generic, and for those that are not, a decades-old
> Supreme Court case allows scientists to perform research on patented
> compounds. It also allows them to make and trade such compounds for
> research purposes -- something known as the Bolar exemption, after the
> now-defunct generic company that fought this case in court.
>
>
>
> Drug rescue is more complicated because much of what is known about these
> candidates has not been published. (Sometimes, even the structure has not
> been disclosed.) Yet, that knowledge is key to figuring out what the drug
> might be good for. So, whoever wants to rescue a drug has to seek the
> collaboration of the patent owner. Pharma companies have recently become
> more open to this. I recently asked 5 big pharma companies whether they
> would entertain letting scientists from academia and other companies rescue
> some of their abandoned drug candidates, if the deal were structured to
> allow them to reacquire the candidate down the road for a "fair value" --
> i.e., right of first refusal. They all said yes, although some stipulated
> that they wanted no liability and no obligation to supply trial material.
>
>
>
> A big challenge in drug repurposing is building a library of approved
> compounds. When NCATS started its efforts some years back, it could not
> even get a list of approved drugs from FDA. (No kidding: it did not exist!)
> It took a couple of years to get that data. When it set out to buy the
> compounds, it found out that many were not available. They had been
> discontinued, or superseded by newer drugs. In quite a few cases, the
> recipe had been lost, and had to be recreated. If the compounds were
> available, the purity was not always acceptable; or the minimum order
> quantity was way too high; or re-supply was haphazard.
>
>
>
> The drug repurposing industry has made big strides in the last couple of
> years. There are now specialized search engines to facilitate the discovery
> of new indications, and companies have been created to supply approved
> drugs "to anyone with an assay". So this is definitely something worth
> considering. If we go that route, we should leverage the experience of the
> pioneers who have been doing it -- e,g., NCATS or scientists such as Atul
> Butte at UCSF.
>
>
>
> Hope this helps.
>
>
>
> b
>
>
>
>
>
> On Mon, Jun 8, 2015 at 8:02 PM, Jaykumar Menon, Prof. <
> jaykumar.menon at mcgill.ca> wrote:
>
>  Dear Peter,
>
>
>
> Thanks for the note and all the superb effort!
>
>
>
> And dear all,
>
>
>
> There is so much to discuss and plan and make sense of, as the open source
> meme seems to be catching on.  (And a quick personal apologia - I’ve been
> buried in things operational – trying to add some heft and muscle to this
> discussion and movement, so sorry for my relative silence of late on the
> email list-serv.)  For the meeting at the Castle, as you can see from the
> spreadsheet, we are already at 14 attendees, a mix of  “new” and “old”
> blood (i.e. those who attended Bellagio and those who did not), hailing
> from San Francisco (Linux Foundation) to Seattle (a special person from
> Gates) to Oxford (Structural Genomics), with some heavy hitters, so let us
> know if you are interested soon, as this is again a small venue, and we are
> trying to get the optimal mix.  Suggestions of people are also welcome.
>
>
>
> As those of you who were at Bellagio remember, this is a special group,
> and a special colloquy and movement, operating in a realm that is at the
> cutting edge of the cutting edge, yet animated by human need.  It is a
> union of those adept at concretizing dreams.  And it is superfun, a bonding
> experience.  Thanks again to Peter for securing such an unbelievable spot.
>
>
>
> And as a precis and discussion starter, a question, perhaps foolish and
> ill-informed, considering the vast expertise in this group, but posed in
> the spirit of risk-taking and thinking big, is appended below.
>
>
>
> With warm regards,
>
> Jaykumar
>
>
>
> *Repurposing (admittedly imprecise and perhaps inaccurate description):*
>   Repurposed drugs offer the prospect of huge cost savings.  The goal of
> repurposing is to deploy approved drugs or abandoned clinical candidates in
> new disease areas.  Directing such drugs – particularly those that are
> fully approved and off patent - towards new diseases can deliver cures at a
> fraction of the cost of developing a new drug.  This is due to savings in
> R&D expense and reduced clinical trial requirements.
>
>
>
> A question came up recently in a discussion with a funder, and we novices
> didn’t know the answer, and I thought I’d take it to the group mind.
>
>
>
> Would it make any sense to have a grand and almost comprehensive
> repurposing project, an Apollo project of sorts, where we look at
> essentially all/large numbers of generic drugs, to see their applicability
> against a particular condition (or many) of (public) health need?  Has it
> already been adequately done?  (There have been  efforts from NIH NCATS,
> working with under-patent drug candidates from pharma companies, but
> evidently not with generics and approved drugs, and other efforts too).
> Would it be at all needed, feasible and fruitful?  If so, crowdsourcing and
> openness would seem to be essential.  It is thus a natural fit for those
> intrigued by open source pharma.
>
>
>
> j
>
>
>
> *From:* Peter Kolb [mailto:peter.kolb at uni-marburg.de]
> *Sent:* Monday, June 08, 2015 1:50 PM
> *To:* opensourcepharma at lists.okfn.org
> *Cc:* Jaykumar Menon, Prof.; Matthew Todd
> *Subject:* OSP @ RHH 2015 will happen Sep 1-3
>
>
>
> Dear past and future OSP participants,
>
> The 2015 meeting will take place on September 1-3, 2015, in castle
> Rauischholzhausen <https://goo.gl/maps/TmERX>, near Marburg (greater
> Frankfurt area), Germany.  Here are some key facts to assist in your
> planning:
>
>    - Arrival is possible from Aug 31, 10am. Departure is on Sep 3 after
>    lunch. The conference program will run from Sep 1 morning until Sep 3 noon.
>    - Please sign up at http://tinyurl.com/osprhh by June 30 in order to
>    participate. This spreadsheet also allows you to record dietary preferences
>    as well as arrival and departure times.
>    - The easiest travel option is to fly into Frankfurt airport (FRA),
>    then take a train <http://www.bahn.de/p_en/view/index.shtml> to
>    Marburg (approx. 90 mins), followed by a short cab ride to the castle. More
>    detailed instructions will follow to participants at a later time.
>    - Accommodation as well as meals and coffee breaks will be provided at
>    the castle.
>    - We have secured some sponsorship and are trying to secure more.  The
>    worst-case scenario, in case we completely fail to do so, will be a lodging
>    fee of EUR 250 per person (covering all accommodation and meals for the 3-4
>    days, which is quite reasonable). Please do not let it be an impediment to
>    registering initially; if you need to drop out later, that will be all
>    right.
>
> If you have any questions, please do not hesitate to write!
>
> Looking forward to a fruitful meeting in September,
> Jay, Mat & Peter
>
> --
>
>
>
> P e t e r   K o l b
>
> Emmy Noether Group Leader
>
> Pharmaceutical Chemistry @ Philipps-University Marburg
>
> Tel +49 6421 28 25908 | Fax +49 6421 28 28994
>
> http://www.kolblab.org
>
>
>
> Chair | GLISTEN: COST Action CM1207
>
> http://www.glisten-gpcr.eu/
>
>
>
> Editor | Journal of Postdoctoral Affairs
>
> http://www.postdocjournal.com
>
>
> _______________________________________________
> opensourcepharma mailing list
> opensourcepharma at lists.okfn.org
> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>
>
>
>
>
> --
>
> Follow me on *Forbes* <http://blogs.forbes.com/bernardmunos/> and
> *Fastercures*
> <http://fastercures.tumblr.com/post/62722481036/give-me-your-innovators-yearning-to-breathe-free#!>
>
>
>
>
> _______________________________________________
> opensourcepharma mailing list
> opensourcepharma at lists.okfn.org
> https://lists.okfn.org/mailman/listinfo/opensourcepharma
>
>

-- 
Follow me on Forbes <http://blogs.forbes.com/bernardmunos/> and Fastercures
<http://fastercures.tumblr.com/post/62722481036/give-me-your-innovators-yearning-to-breathe-free#!>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20150609/267b2cc5/attachment-0002.html>